Mohit Bansal
Stock Analyst at Wells Fargo
(4.14)
# 467
Out of 4,876 analysts
166
Total ratings
60%
Success rate
10.04%
Average return
Main Sectors:
Stocks Rated by Mohit Bansal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Downgrades: Equal-Weight | $700 → $580 | $522.11 | +11.09% | 18 | May 30, 2025 | |
| XENE Xenon Pharmaceuticals | Maintains: Overweight | $50 → $47 | $32.66 | +43.91% | 2 | May 13, 2025 | |
| HALO Halozyme Therapeutics | Maintains: Equal-Weight | $60 → $65 | $52.53 | +23.74% | 7 | May 7, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Equal-Weight | $62 → $53 | $46.66 | +13.60% | 9 | Apr 28, 2025 | |
| IRWD Ironwood Pharmaceuticals | Downgrades: Equal-Weight | $7 → $1 | $0.74 | +34.93% | 4 | Apr 15, 2025 | |
| LLY Eli Lilly and Company | Maintains: Overweight | $970 → $1,100 | $784.80 | +40.16% | 17 | Mar 5, 2025 | |
| GILD Gilead Sciences | Maintains: Overweight | $120 → $140 | $110.78 | +26.38% | 11 | Mar 5, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $210 → $240 | $185.50 | +29.38% | 8 | Mar 5, 2025 | |
| BIIB Biogen | Maintains: Equal-Weight | $165 → $140 | $126.55 | +10.63% | 13 | Feb 13, 2025 | |
| JAZZ Jazz Pharmaceuticals | Upgrades: Overweight | $130 → $170 | $107.91 | +57.54% | 2 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Equal-Weight | $460 | $446.59 | +3.00% | 10 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $335 → $280 | $280.00 | - | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $20.96 | +43.13% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $170 | $106.55 | +59.55% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $70 | $23.27 | +200.82% | 1 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $125 → $110 | $78.88 | +39.45% | 10 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $9 → $27 | $15.12 | +78.57% | 4 | Oct 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $115 → $90 | $54.83 | +64.14% | 5 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $28 → $30 | $24.26 | +23.69% | 10 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $140 → $170 | $126.47 | +34.42% | 7 | Apr 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $27 | $13.86 | +94.81% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $1,875 | $12.45 | +14,960.24% | 1 | Mar 26, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $30 | $29.63 | +1.27% | 4 | Jan 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $1.00 | +3,489.23% | 1 | Nov 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $19 | $13.66 | +39.09% | 3 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $5 | $0.24 | +2,018.64% | 3 | Apr 27, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $30 → $60 | $1.05 | +5,614.29% | 4 | Dec 3, 2019 |
Regeneron Pharmaceuticals
May 30, 2025
Downgrades: Equal-Weight
Price Target: $700 → $580
Current: $522.11
Upside: +11.09%
Xenon Pharmaceuticals
May 13, 2025
Maintains: Overweight
Price Target: $50 → $47
Current: $32.66
Upside: +43.91%
Halozyme Therapeutics
May 7, 2025
Maintains: Equal-Weight
Price Target: $60 → $65
Current: $52.53
Upside: +23.74%
Bristol-Myers Squibb Company
Apr 28, 2025
Maintains: Equal-Weight
Price Target: $62 → $53
Current: $46.66
Upside: +13.60%
Ironwood Pharmaceuticals
Apr 15, 2025
Downgrades: Equal-Weight
Price Target: $7 → $1
Current: $0.74
Upside: +34.93%
Eli Lilly and Company
Mar 5, 2025
Maintains: Overweight
Price Target: $970 → $1,100
Current: $784.80
Upside: +40.16%
Gilead Sciences
Mar 5, 2025
Maintains: Overweight
Price Target: $120 → $140
Current: $110.78
Upside: +26.38%
AbbVie
Mar 5, 2025
Maintains: Overweight
Price Target: $210 → $240
Current: $185.50
Upside: +29.38%
Biogen
Feb 13, 2025
Maintains: Equal-Weight
Price Target: $165 → $140
Current: $126.55
Upside: +10.63%
Jazz Pharmaceuticals
Feb 13, 2025
Upgrades: Overweight
Price Target: $130 → $170
Current: $107.91
Upside: +57.54%
Jan 30, 2025
Downgrades: Equal-Weight
Price Target: $460
Current: $446.59
Upside: +3.00%
Jan 10, 2025
Maintains: Equal-Weight
Price Target: $335 → $280
Current: $280.00
Upside: -
Dec 11, 2024
Initiates: Overweight
Price Target: $30
Current: $20.96
Upside: +43.13%
Dec 11, 2024
Initiates: Overweight
Price Target: $170
Current: $106.55
Upside: +59.55%
Nov 21, 2024
Initiates: Overweight
Price Target: $70
Current: $23.27
Upside: +200.82%
Nov 1, 2024
Maintains: Equal-Weight
Price Target: $125 → $110
Current: $78.88
Upside: +39.45%
Oct 21, 2024
Upgrades: Overweight
Price Target: $9 → $27
Current: $15.12
Upside: +78.57%
Sep 17, 2024
Maintains: Overweight
Price Target: $115 → $90
Current: $54.83
Upside: +64.14%
Jul 31, 2024
Maintains: Equal-Weight
Price Target: $28 → $30
Current: $24.26
Upside: +23.69%
Apr 24, 2024
Upgrades: Overweight
Price Target: $140 → $170
Current: $126.47
Upside: +34.42%
Mar 7, 2023
Initiates: Overweight
Price Target: $27
Current: $13.86
Upside: +94.81%
Mar 26, 2021
Initiates: Buy
Price Target: $1,875
Current: $12.45
Upside: +14,960.24%
Jan 7, 2021
Maintains: Buy
Price Target: $25 → $30
Current: $29.63
Upside: +1.27%
Nov 3, 2020
Initiates: Buy
Price Target: $36
Current: $1.00
Upside: +3,489.23%
Apr 30, 2020
Maintains: Buy
Price Target: $16 → $19
Current: $13.66
Upside: +39.09%
Apr 27, 2020
Maintains: Buy
Price Target: $8 → $5
Current: $0.24
Upside: +2,018.64%
Dec 3, 2019
Upgrades: Neutral
Price Target: $30 → $60
Current: $1.05
Upside: +5,614.29%